382 related articles for article (PubMed ID: 30057972)
1. The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management.
Girotra M; Hansen A; Farooki A; Byun DJ; Min L; Creelan BC; Callahan MK; Atkins MB; Sharon E; Antonia SJ; West P; Gravell AE;
JNCI Cancer Spectr; 2018 Jul; 2(3):pky021. PubMed ID: 30057972
[TBL] [Abstract][Full Text] [Related]
2. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies.
Byun DJ; Wolchok JD; Rosenberg LM; Girotra M
Nat Rev Endocrinol; 2017 Apr; 13(4):195-207. PubMed ID: 28106152
[TBL] [Abstract][Full Text] [Related]
3. Endocrine side effects of cancer immunotherapy.
Cukier P; Santini FC; Scaranti M; Hoff AO
Endocr Relat Cancer; 2017 Dec; 24(12):T331-T347. PubMed ID: 29025857
[TBL] [Abstract][Full Text] [Related]
4. Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.
Del Rivero J; Cordes LM; Klubo-Gwiezdzinska J; Madan RA; Nieman LK; Gulley JL
Oncologist; 2020 Apr; 25(4):290-300. PubMed ID: 32297436
[TBL] [Abstract][Full Text] [Related]
5. Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review.
Stelmachowska-Banaś M; Czajka-Oraniec I
Endocr Connect; 2020 Oct; 9(10):R207-R228. PubMed ID: 33064663
[TBL] [Abstract][Full Text] [Related]
6. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Weber JS; Postow M; Lao CD; Schadendorf D
Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
[TBL] [Abstract][Full Text] [Related]
7. How we treat endocrine complications of immune checkpoint inhibitors.
Paschou SA; Stefanaki K; Psaltopoulou T; Liontos M; Koutsoukos K; Zagouri F; Lambrinoudaki I; Dimopoulos MA
ESMO Open; 2021 Feb; 6(1):100011. PubMed ID: 33399077
[TBL] [Abstract][Full Text] [Related]
8. UPDATES IN ENDOCRINE IMMUNE-RELATED ADVERSE EVENTS IN ONCOLOGY IMMUNOTHERAPY.
Coniac S; Stoian M
Acta Endocrinol (Buchar); 2021; 17(2):286-289. PubMed ID: 34925584
[TBL] [Abstract][Full Text] [Related]
9. Endocrine side effects induced by immune checkpoint inhibitors.
Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitor therapy for pediatric cancers: A mini review of endocrine adverse events.
Ihara K
Clin Pediatr Endocrinol; 2019; 28(3):59-68. PubMed ID: 31384097
[TBL] [Abstract][Full Text] [Related]
11. Monitoring Endocrine Complications of Immunotherapy: A Screening Tool.
Majety P; Groysman A; Seery V; Shea M; Hou R
Cureus; 2022 Jul; 14(7):e26859. PubMed ID: 35974849
[TBL] [Abstract][Full Text] [Related]
12. Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know).
Ruggeri RM; Campennì A; Giuffrida G; Trimboli P; Giovanella L; Trimarchi F; Cannavò S
J Endocrinol Invest; 2019 Jul; 42(7):745-756. PubMed ID: 30471004
[TBL] [Abstract][Full Text] [Related]
13. Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy.
Kumar V; Chaudhary N; Garg M; Floudas CS; Soni P; Chandra AB
Front Pharmacol; 2017; 8():49. PubMed ID: 28228726
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities.
Villadolid J; Amin A
Transl Lung Cancer Res; 2015 Oct; 4(5):560-75. PubMed ID: 26629425
[TBL] [Abstract][Full Text] [Related]
15. Endocrine sequelae of immune checkpoint inhibitors.
Ntali G; Kassi E; Alevizaki M
Hormones (Athens); 2017 Oct; 16(4):341-350. PubMed ID: 29518754
[TBL] [Abstract][Full Text] [Related]
16. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
17. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management.
Sznol M; Postow MA; Davies MJ; Pavlick AC; Plimack ER; Shaheen M; Veloski C; Robert C
Cancer Treat Rev; 2017 Jul; 58():70-76. PubMed ID: 28689073
[TBL] [Abstract][Full Text] [Related]
18. Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario.
Spagnolo CC; Giuffrida G; Cannavò S; Franchina T; Silvestris N; Ruggeri RM; Santarpia M
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612243
[TBL] [Abstract][Full Text] [Related]
19. [Clinical practice and mechanism of endocrinological adverse events associated with immune checkpoint inhibitors].
Iwama S; Arima H
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):90-94. PubMed ID: 28603206
[TBL] [Abstract][Full Text] [Related]
20. Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist.
Weber JS
Am Soc Clin Oncol Educ Book; 2012; ():174-7. PubMed ID: 24451730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]